Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II, 12-week, multicentre, randomised trial investigating ETC 1002 in patients with hypercholesterolaemia with or without high triglycerides.

Next Previous
X
Search
Trial Profile

Phase II, 12-week, multicentre, randomised trial investigating ETC 1002 in patients with hypercholesterolaemia with or without high triglycerides.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bempedoic acid (Primary)
  • Indications Hypercholesterolaemia
  • Focus Biomarker; Proof of concept; Therapeutic Use
  • Sponsors Esperion Therapeutics

    • Most Recent Events

    • 12 Jun 2013 Results published in the Journal of the American College of Cardiology.
    • 26 Mar 2012 Results were reported at the 61st Annual American College of Cardiology Meeting, according to an Esperion Therapeutics media release.
    • 01 Oct 2011 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top